Affordable Access

Access to the full text

The meta-memory ratio: a new cohort-independent way to measure cognitive awareness in asymptomatic individuals at risk for Alzheimer’s disease

  • Gagliardi, Geoffroy1, 2
  • Houot, Marion2, 3
  • Cacciamani, Federica1, 2, 4
  • Habert, Marie-Odile5, 6, 7
  • Dubois, Bruno1, 2, 3
  • Epelbaum, Stéphane1, 2, 4
  • Audrain, C.
  • Auffret, A.
  • Bakardjian, H.
  • Baldacci, F.
  • Batrancourt, B.
  • Benakki, I.
  • Benali, H.
  • Bertin, H.
  • Bertrand, A.
  • Boukadida, L.
  • Cacciamani, F.
  • Causse, V.
  • Cavedo, E.
  • Cherif Touil, S.
  • And 55 more
  • 1 Institut du cerveau et de la moelle (ICM) - Hôpital Pitié-Salpêtrière, Paris, France , Paris (France)
  • 2 Institut de la mémoire et de la maladie d’Alzheimer, Paris, France , Paris (France)
  • 3 University Paris 6, Paris, France , Paris (France)
  • 4 Aramis project-team, Inria-APHP collaboration, Paris, F-75013, France , Paris (France)
  • 5 Sorbonne Universités, CNRS, INSERM, Laboratoire d’Imagerie Biomédicale, Paris, France , Paris (France)
  • 6 Centre pour l’Acquisition et le Traitement des Images, Paris, France , Paris (France)
  • 7 AP-HP, Hôpital Pitié-Salpêtrière, Paris, France , Paris (France)
Published Article
Alzheimer's Research & Therapy
BioMed Central
Publication Date
May 14, 2020
DOI: 10.1186/s13195-020-00626-1
Springer Nature


BackgroundLack of awareness of cognitive decline (ACD) has been described at the preclinical and prodromal stages of Alzheimer’s disease (AD). In this study, we introduced a meta-memory ratio (MMR) and explored how it is associated with neuroimaging AD biomarkers in asymptomatic individuals at risk for AD.MethodFour hundred forty-eight cognitively healthy participants from two cohorts of subjective memory complainers (INSIGHT-PreAD and ADNI) were included. Regression models were used to assess the impact of AD biomarkers on the MMR.ResultIn both cohorts, there was a significant quadratic effect of cerebral amyloidosis on the MMR value. In particular, participants had a high ACD up to the amyloid positivity threshold, above which a decrease of ACD was eventually observed as the amyloid load increased.ConclusionThis nonlinear evolution of ACD in very early AD must be taken into account in clinical care and for trial enrollment as well.

Report this publication


Seen <100 times